Selectquote, INC

Market Movers (8-K)

See all →
NYSE
SelectQuote, Inc. announced its first quarter fiscal year 2027 financial results, reporting a net loss of $20.3 million but a substantial year-over-year improvement in Adjusted EBITDA to $(17.0) million.
NYSE
SelectQuote, Inc. announced its fourth quarter and full fiscal year 2026 results, highlighting a significant improvement in operating cash flow and strong performance in its Senior segment, while also reporting a net loss for the quarter and a decrease in full-year Adjusted EBITDA.
Worse than expected
NYSE
SelectQuote, Inc. announced its third quarter fiscal year 2026 financial results, showcasing revenue growth and improved profitability.
NYSE
SelectQuote, Inc. received a notice from the NYSE for non-compliance due to its common stock trading below $1.00 for 30 consecutive days, initiating a six-month cure period.
Worse than expected
NYSE
SelectQuote, Inc. reported a 12% increase in consolidated revenue for the second quarter of fiscal year 2026, reaching $537.1 million, but revised its full-year guidance downwards due to partner-driven headwinds.
Worse than expected
Capital raise
NYSE
SelectQuote, Inc. announced a new $415 million credit facility, comprising a $325 million term loan and a $90 million revolving credit facility, significantly extending its debt maturity to January 2031 and enhancing liquidity.
Better than expected
Capital raise

Quarterly Earnings (10-Q)

See all →
NYSE
SelectQuote reported a 15% year-over-year revenue decrease for the third quarter of 2026, driven by declines in both its Senior and Healthcare Services segments, alongside a net loss.
Worse than expected
NYSE
SelectQuote reports a 12% revenue increase for the six months ended December 31, 2025, driven by its Healthcare Services segment, alongside a significant debt refinancing and ongoing legal challenges.
Capital raise
NYSE
SelectQuote, Inc. reported a wider net loss attributable to common shareholders in Q1 2026, driven by a significant decline in its Senior insurance segment despite growth in Healthcare Services.
Worse than expected
Capital raise
NYSE
SelectQuote's Q3 2025 results reveal a revenue increase driven by pharmacy services, overshadowed by a DOJ investigation and a decline in Senior segment performance.
Worse than expected
NYSE
SelectQuote, Inc. reports a rise in revenue and income from operations for the quarter ended December 31, 2024, driven by growth in its Senior and Healthcare Services segments.
Better than expected
Capital raise
NYSE
SelectQuote's first quarter of fiscal year 2025 shows a 26% increase in total revenue, primarily driven by a 61% surge in pharmacy revenue, while the company navigates ongoing financial challenges.
Worse than expected
Capital raise

Annual Reports (10-K)

NYSE
SelectQuote, Inc. files its annual report, detailing its capital stock structure, anti-takeover provisions, and corporate governance, alongside financial performance and risk factors.
Worse than expected
NYSE
SelectQuote, a leading insurance distributor, pivots to healthcare services, achieving net income in fiscal year 2025 despite a decline in its core Senior insurance segment.
Capital raise
NYSE
SelectQuote, Inc. released its annual 10-K filing, detailing its business model, financial performance, and strategic outlook for the coming year.
Worse than expected
Capital raise

Insider Trading (Form 4)

See all →
NYSE
Chris Wolfe, a Director of SelectQuote, Inc., reported multiple transactions in common stock on November 10, 2026.
NYSE
Earl H Devanny Iii, a Director of SelectQuote, Inc., reported multiple transactions in common stock on November 10, 2026.
NYSE
Donald L Hawks Iii, a Director of SelectQuote, Inc., reported multiple transactions in common stock on November 10, 2026.
NYSE
Denise L Devine, a Director of SelectQuote, Inc., reported multiple transactions in common stock on November 10, 2026.
NYSE
Raymond F Weldon, a Director of SelectQuote, Inc., reported multiple transactions in common stock on November 10, 2026.
NYSE
Kavita Patel, a Director of SelectQuote, Inc., reported multiple transactions in common stock on November 10, 2026.

Proxy Statements (Def-14A)

NYSE
SelectQuote, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for November 10, 2026, to be held virtually, with key proposals including the election of directors, ratification of auditors, executive compensation approval, and a significant reverse stock split proposal.
Worse than expected
NYSE
SelectQuote, Inc. has filed a definitive proxy statement with the SEC, indicating an upcoming shareholder meeting.
NYSE
SelectQuote, Inc. announces robust fiscal year 2025 financial results, including significant revenue growth and a strategic capital raise, ahead of its 2025 Annual Meeting of Stockholders.
Better than expected
Capital raise
Delay expected
NYSE
SelectQuote, Inc. has filed a definitive proxy statement with the SEC pursuant to Section 14(a) of the Securities Exchange Act of 1934.
NYSE
SelectQuote, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on November 12, 2024, to vote on director elections, auditor ratification, and executive compensation.

Schedule 13G - Passive Investments

NYSE
Morgan Stanley filed an amended Schedule 13G to clarify its beneficial ownership in SelectQuote, Inc., adjusting for warrant exercise limitations.
NYSE
Morgan Stanley has reported a 5.6% beneficial ownership stake in SelectQuote, Inc.'s common stock, held for passive investment purposes.